Timing note: July 22, 2026 is today, not tomorrow. PM is scheduled to report before the U.S. market opens on Wednesday, July 22, 2026. No second-quarter earnings release was available in the research database at the time of writing, so this is a pre-results preview.
PM enters the report with strong international smoke-free momentum but a demanding valuation and unresolved questions around U.S. ZYN growth. The quarter itself may be somewhat noisy because of ZYN inventory comparisons, Japan excise-related timing and a noncash Canadian impairment. The more important question is whether management can support a stronger second half without further reducing guidance.
The market is looking for approximately:
| Q2 metric | Expectation / prior guidance |
|---|---|
| Adjusted EPS | Approximately $2.07 |
| Organic revenue growth | Approximately 5% |
| Smoke-free organic growth | Approximately 10.3% |
| PM adjusted EPS guidance | $8.31–$8.46 |
| Q2 HTU shipments | 40–42 billion units |
| Cigarette shipments | Low-single-digit decline |
The central debate is straightforward:
PM closed July 21 at $188.07, up roughly 17% year to date and almost 15% since its first-quarter report. The stock trades at approximately 22.4 times the midpoint of current adjusted EPS guidance and offers a roughly 3.1% annualized dividend yield.
That is a premium setup for a tobacco company. Investors are increasingly valuing PM as a differentiated consumer-growth business because of IQOS and ZYN. Consequently, simply meeting the quarterly EPS estimate may not be sufficient. The stock likely needs:
First-quarter U.S. segment results were weak:
The gap between shipments and consumer purchases reflected two inventory effects: a roughly 40-million-can inventory rebuild in Q1 2025 and the removal of approximately 25 million excess cans from the downstream channel during Q1 2026. Increased promotions and manufacturing costs also pressured profitability.
Management identified approximately 180 million cans as the underlying Q2 2025 shipment base. As a practical benchmark, a Q2 result around 190–200 million cans would suggest that shipments are again broadly tracking underlying category demand, although product-launch inventory could complicate the comparison.
The report should answer four questions:
Has ZYN’s consumer growth stabilized?
At the Q1 call, management acknowledged that the latest weekly Nielsen growth had slowed to approximately 5%–6%, versus 10% for the full quarter.
Is PM closing the product gap with competitors?
ZYN historically lacked exposure to some of the faster-growing higher-strength and fruit-flavor segments.
How much promotion is required?
PM wants ZYN to retain a premium position, but its price gap versus competitors has become a concern. ZYN Ultra is being priced at a lower cost per pouch than the flagship range, which should improve competitiveness but may pressure revenue per can.
When does U.S. profitability recover?
Management previously said Q2 would still face difficult promotion and inventory comparisons, with more meaningful improvement expected in the second half.
Bottom line: A weak U.S. quarter can be forgiven if management presents credible evidence that ZYN growth and profitability will improve in H2. Another vague promise of future normalization would be less well received.
International smoke-free was PM’s standout business in Q1:
This performance is the primary reason investors are willing to overlook near-term U.S. weakness.
Japan will create difficult sequential comparisons:
Investors should avoid overreacting to a mechanically slower Japan growth rate. The more useful indicators are:
A good Q2 would show that the Japan disruption is temporary and that IQOS remains capable of high-single-digit or better underlying growth across a broad geographic base.
Investors often focus almost exclusively on U.S. ZYN, but PM’s international multi-category portfolio is increasingly important.
Q1 e-vapor shipments nearly doubled and surpassed one billion equivalent units for the first time. PM said VEEV had reached the joint No. 1 closed-pod position in Europe, with strong growth in markets including Italy, Germany, the U.K., France, Spain and Romania.
The questions for Q2 are:
Outside the mature Nordic markets, international modern-oral offtake grew by more than 50% in Q1. Expansion in the U.K., Pakistan, Poland and Mexico was particularly strong.
This business remains small relative to IQOS and U.S. ZYN, but sustained growth would strengthen the argument that PM owns a globally scalable nicotine platform rather than one or two isolated brands.
PM’s cigarette business continues to finance its smoke-free expansion. Q1 demonstrated both the strength and limits of that model:
Management expects the full-year cigarette decline to moderate to approximately 3% and forecast a low-single-digit decline for Q2. It also raised its full-year combustible pricing expectation to more than 6%.
Mexico’s excise increase, weaker consumer conditions in Germany, industry disruption in India and share pressure in Indonesia and Russia all bear watching. If pricing no longer offsets volume weakness, the market may question whether PM is extracting too much value from the combustible consumer base.
PM delivered strong international gross-profit growth in Q1, but consolidated organic operating-income growth was only modest because of:
Management warned that Q2 would contain another period of substantial commercial investment, followed by more moderate spending growth in H2. It nevertheless expects full-year organic operating-margin expansion.
The desired Q2 message is therefore not necessarily large margin expansion. Instead, investors need:
A revenue beat funded entirely by promotion and marketing would be lower quality than a modest top-line beat accompanied by better gross profit and operating leverage.
PM initially guided to adjusted 2026 EPS of $8.36–$8.51 following Q1. On June 2, it lowered that range by $0.05 to $8.31–$8.46, primarily because of currency changes.
Current underlying guidance remains:
The key issue is whether PM can maintain these targets after absorbing:
Given the valuation, another guidance reduction—even if largely currency-related—could overshadow a small Q2 earnings beat. Conversely, maintaining guidance while raising confidence in H2 ZYN performance would probably be viewed favorably.
PM expects an approximately $500 million noncash impairment charge related to its investment in Canadian affiliate Rothmans, Benson & Hedges. This should create a sizable difference between GAAP and adjusted earnings.
The market is likely to exclude it from the operating assessment, but management should explain whether it reflects company-specific deterioration, changes in litigation assumptions or broader regulatory risk.
Massimo Andolina, currently President of Europe, becomes group CFO on August 1, 2026, replacing Emmanuel Babeau. Babeau will remain as a strategic adviser through March 2027.
This report is therefore likely to be Babeau’s final earnings call as CFO. Investors should listen for continuity in financial targets, capital allocation, debt reduction and reporting philosophy under Andolina.
PM ended Q1 with $51.9 billion of total debt, although seasonal working-capital requirements inflated short-term borrowing. Full-year operating cash-flow guidance was approximately $13.5 billion, with capital expenditure of $1.4–$1.6 billion.
Investors will want confirmation that cash generation remains sufficient to fund:
PM’s Q2 report is less about whether adjusted EPS lands a few cents above or below $2.07 and more about whether the company’s growth mix is evolving as promised.
The international business appears healthy: IQOS remains the core earnings engine, while VEEV and international ZYN are adding breadth. The principal uncertainty is the United States, where PM needs to show that ZYN’s recent slowdown is addressable through inventory normalization, improved pricing, ZYN Ultra and the newly authorized modified-risk claim.
At roughly 22 times current-year guidance, investors are already paying for successful execution. A clean report with maintained guidance and credible H2 U.S. improvement could support the premium. A second guidance disappointment or further deterioration in ZYN would leave little valuation cushion.